According to a recent survey, active adults aren’t slowing down. The survey found that 62 percent of adults ages 30-49 continue to work out as much – and with the same or more intensity – as they did in their 20s. More than half would like to ramp up their performance and do more of what they love, but are stopped by pain and the risk of injuries.
Massage Envy’s new, proprietary assisted stretching service, called Total Body Stretch, is designed to help people perform at their best, ease the muscle pain and tension that comes with activity, and resist injuries.
Developed for Massage Envy by an acclaimed chiropractor, massage therapist and ergonomist and performed by a stretching professional, the Total Body Stretch service is built around the company’s proprietary Streto Method, a sequence of 10 targeted stretches designed to increase flexibility, mobility and performance.
To view the multimedia release go to:
https://www.multivu.com/players/English/8133351-massage-envy-streto-total-body-stretch/
Building on a successful campaign that helped hundreds of thousands of Americans learn their risk of developing type 2 diabetes through campaign messaging and an online risk test, the first-of-its-kind initiative to raise national awareness of prediabetes returns with an entertaining new approach. The new campaign, launching today, encourages viewers to take a one-minute prediabetes risk test to know where they stand and discover how they can decrease their risk of developing type 2 diabetes — and it does so with some adorable helpers.
More than one in three American adults has prediabetes — a serious health condition that often leads to type 2 diabetes and other significant health conditions like blindness, heart attack or stroke. According to newly released CDC data, however, nearly 90 percent of the 84 million people with prediabetes don’t know they have it and aren’t aware of the long-term risks to their health. Currently, about 30 million Americans are living with diabetes.
To view the multimedia release go to:
https://www.multivu.com/players/English/8142351-ad-council-prediabetes/
Abila, the leading provider of software and services to nonprofits, associations, and government entities, announced today findings from its Nonprofit Finance Study: Managing Growth. This study explores the trends and challenges associated with nonprofit growth, including how organizations plan to grow in the next few years, growth’s impact on risk management and compliance, and the difficulties maintaining organizational culture during growth.
“Approximately 80 percent of surveyed nonprofits say they plan to grow in the next 12 to 18 months,” said Dan Murphy, senior manager of fund accounting strategy for Abila, and study co-author. “However, oftentimes, with growth comes increased complexity. For example, managing risk, maintaining compliance, and retaining an organization’s unique culture becomes more challenging as organizations adopt a wide variety of growth strategies. Those nonprofits that understand and plan for growth now and in the near future will be primed for success.”
To view the multimedia release go to:
https://www.multivu.com/players/English/7858254-abila-nonprofit-finance-study/
Changes in the treatment of pediatric cancer over recent decades have translated to a reduced risk of serious, long-term late health effects of cancer therapy. This is according to the latest analysis from the Childhood Cancer Survivor Study (CCSS), a National Cancer Institute-funded resource for late-effects research, led by investigators at St. Jude Children’s Research Hospital.
“This is the first comprehensive study to demonstrate how changes in treatments over time have impacted the occurrence of late effects experienced by childhood cancer survivors,” said Todd Gibson, Ph.D., assistant member of the Department of Epidemiology and Cancer Control at St. Jude. “We found the 15-year cumulative incidence of people reporting at least one severe health condition decreased from 12.7 percent among childhood cancer survivors diagnosed in the 1970s to 10.1 percent for those diagnosed in the 1980s to 8.8 percent in the 1990s–a statistically significant decline.”
To view the multimedia release go to:
https://www.multivu.com/players/English/7924756-st-jude-childhood-cancer-survivorship-asco-2017/
Recognizing an opportunity to create a better world through innovative energy solutions, ENGIE Resources, the third-largest non-residential electricity provider in the United States, has unveiled a new program designed to put more power where it belongs – in the hands of customers.
Called the “Energy Revolution,” the effort seeks to shift the emphasis away from providers’ traditional role, which has been to help customers manage price risk alone, and toward helping customers manage both price and quantity – how much they use, when they use it, and what they pay.
To view the multimedia release go to:
https://www.multivu.com/players/English/8071951-engie-resources-leads-energy-revolution/
See America, Allergan’s initiative to fight against preventable blindness in the United States, today unveiled a powerful video featuring award-winning actor and hip-hop artist Common, that urges Americans to “stand in the way of darkness”.
The video harnesses Common’s striking spoken word ability, calling on Americans to fight against vision loss and prioritize their vision. Common highlights the 61 million Americans at-risk of severe vision loss, and challenges us all to imagine a life without sight.
“I'm proud to join Allergan in the fight against preventable blindness,” said Common. “Sight is something that far too many of us take for granted. I hope our message resonates with people across the country, no matter what age or background.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8057551-common-joins-allergan-see-america-against-preventable-blindness/
The Ad Council, the largest producer of public service campaigns in the U.S., in partnership with Viacom, home to premier global brands in media and entertainment, and non-profit leader Facing Addiction today launched the PSA campaign “LISTEN” to ignite a national conversation about drug and alcohol addiction as a public health epidemic, and empower those impacted by substance use disorders.
While past PSA campaigns have traditionally focused on the perspective of those at risk, urging them to eliminate all substance use, “LISTEN” addresses the support system of people who are also affected by this crisis. Using powerful stories that portray the modern faces of addiction and recovery, the campaign looks to remove the stigma attached to substance misuse through the act of informed, compassionate listening. The campaign’s website, heretolisten.com, and Facing Addiction's Resource Hub provides important tools and information to help people start a productive conversation with their friends and loved ones and to support the more than 45 million Americans directly impacted by addiction.
To view the multimedia release go to:
http://www.multivu.com/players/English/8029751-ad-council-listen-psa-addiction-drug-alcohol-substance-abuse/
Every 23 seconds, someone in the United States is diagnosed with diabetes. It's estimated that one in 11 Americans has the disease—more than 29 million people—and another 86 million have prediabetes and are at risk for developing type 2 diabetes. The numbers alone are staggering, and the people affected by the disease include those who have diabetes and their friends, family, caregivers and communities.
American Diabetes Month®, observed by the American Diabetes Association® (Association) every November, is a time to focus the nation's attention on the many people who are affected by diabetes and to raise the urgency about the need to address diabetes. To help spark a national conversation, the Association is asking people to share their stories about what it truly means to live with diabetes with a new campaign, This Is Diabetes™.
http://www.multivu.com/players/English/7711431-american-diabetes-month-thisisdiabetes/
LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today recognizes that more than one million people in the United States with drug-resistant epilepsy continue to be treated unsuccessfully with drugs, despite the proven effectiveness of non-drug treatment options. LivaNova’s VNS Therapy®, for example, is a medical device treatment specifically designed for people with drug-resistant epilepsy that is already used by more than 85,000 people around the world.
One in three people with epilepsy has the type that is not well controlled with drugs, called drug-resistant epilepsy. For those people, prescribing more medicine is usually not the most effective option. In fact, research shows that if you haven’t found seizure freedom after your first two drugs, there is a 95 percent chance that no drug or combination of drugs will result in seizure freedom.
“Despite what we know about drug-resistant epilepsy, the majority of people affected by this condition will continue to be prescribed additional medications instead of being evaluated for surgery or seen in a specialized epilepsy facility,” said Jason Richey, president of LivaNova’s U.S. Region and general manager of the Neuromodulation Business Franchise. “This treatment gap means over one million individuals in the U.S. with undertreated epilepsy remain at risk for dangerous side effects of continued seizures, including injury, depression, memory issues and death.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7966451-livanova-vns-therapy-epilepsy/
Every 23 seconds, someone in the United States is diagnosed with diabetes. It's estimated that one in 11 Americans has the disease—more than 29 million people—and another 86 million have prediabetes and are at risk for developing type 2 diabetes. The numbers alone are staggering, and the people affected by the disease include those who have diabetes and their friends, family, caregivers and communities.
American Diabetes Month®, observed by the American Diabetes Association® (Association) every November, is a time to focus the nation's attention on the many people who are affected by diabetes and to raise the urgency about the need to address diabetes. To help spark a national conversation, the Association is asking people to share their stories about what it truly means to live with diabetes with a new campaign, This Is Diabetes™.
To view the multimedia release go to:
http://www.multivu.com/players/English/7711431-american-diabetes-month-thisisdiabetes/
A ten-month clinical trial at Sentara Leigh Hospital in Norfolk, Virginia has determined that hard surfaces and linens infused with copper oxide compounds contributed to an 83% reduction in C-difficile and a 78% overall reduction in a host of multi-drug resistant organisms (MDROs) including C-diff, MRSA and VRE in a real-world clinical environment. These results occurred in a hospital with a robust protocol for managing infection risk certified by the health care accrediting body DNV-GL Healthcare.
The results of the trial were published in the peer-reviewed American Journal of Infection Control on Sept. 28, 2016 and will be presented at the annual conference of the Infectious Disease Society of America in New Orleans, Louisiana on October 27, 2016.
To view the multimedia release go to:
http://www.multivu.com/players/English/7955751-sentara-healthcare-infections-copper-clinical-trial/
A ten-month clinical trial at Sentara Leigh Hospital in Norfolk, Virginia has determined that hard surfaces and linens infused with copper oxide compounds contributed to an 83% reduction in C-difficile and a 78% overall reduction in a host of multi-drug resistant organisms (MDROs) including C-diff, MRSA and VRE in a real-world clinical environment. These results occurred in a hospital with a robust protocol for managing infection risk certified by the health care accrediting body DNV-GL Healthcare.
The results of the trial were published in the peer-reviewed American Journal of Infection Control on Sept. 28, 2016 and will be presented at the annual conference of the Infectious Disease Society of America in New Orleans, Louisiana on October 27, 2016.
To view the multimedia release go to:
http://www.multivu.com/players/English/7955751-sentara-healthcare-infections-copper-clinical-trial/
